Lumen Technologies, Inc. (LUMN)

Lumen Technologies shares rose 9.03% in the latest session, but the stock is still down 55.10% over the past year and trades below its 50-day and 200-day moving averages ($5.51 and $7.11). The bounce comes after a November 4, 2026 report in which adjusted EPS of -$0.14 beat the -$0.24 analyst estimate, yet the shares fell 10.96% in the next session. The market is still pricing in a shrinking top line and a business that loses money on a GAAP basis, so the earnings beat has not restored confidence. CleaRank rates the stock Sell with a score of 32/100, more cautious than the Hold consensus on Wall Street.

The November 4, 2026 report was the second straight quarter in which Lumen beat the EPS estimate, with adjusted EPS of -$0.14 against an expected -$0.24. Over the last five reports the company beat four times, but each of those four beats was followed by a lower share price in the first session, including a 10.96% drop after the November report.

Of nine analysts with a current rating, none rate the stock buy or strong buy, eight rate it hold and one rates it sell. Three months ago the count was one buy out of eleven ratings. On November 5, 2026, TD Cowen, Goldman Sachs, Wells Fargo and JP Morgan each kept their existing rating, and Citigroup did the same on November 6, 2026. The median 12-month target is $7.50, which is 59.2% above the price, but the lowest target of $5.00 is still above the current price.

The net profit margin is -5.83% and the operating margin is -7.26%, and the stock trades at a price-to-sales ratio of 0.42 against a sector median of 2.5. That discount reflects the market's doubts about the top line rather than a bargain on earnings, and the company's health score is 2 out of 5.

The base case is that the stock stays in a range below its moving averages while the business works through a shrinking top line. Analysts expect revenue to fall 10.5% this fiscal year, and their average EPS estimate of -$0.57 for 2026 and -$0.31 for 2027 shows losses narrowing but not disappearing. For the shares to improve in a sustained way, the 50-day SMA at $5.51 would need to be reclaimed and held, followed by the 200-day SMA at $7.11. Stronger revenue trends or a shift toward positive earnings would support that path. The downside case is a break below the 20-day EMA at $4.68 and a test of the 52-week low at $3.84, which would happen if revenue declines continue or another report disappoints. The median analyst target of $7.50 sits well above the current price, but the range of targets from $5.00 to $9.00 and the Hold consensus show that analysts are not convinced of a rebound.

Support sits first at the 20-day EMA of $4.68, which the price is only just above; a fall through it would bring the next test. Below that is the 52-week low of $3.84, the lowest price in the past year and the level where buyers have stepped in before. Resistance starts at the 50-day SMA of $5.51, a level the price has been trading beneath. Above it is the 200-day SMA of $7.11, a longer-term trend line that the stock has not reclaimed. The 52-week high of $11.30 is the furthest level overhead.